Spin-off company Endo Axiom founded by three University of Sydney and Sydney Local Health District researchers – has received $2.8 million in backing from Australian biotech incubator Proto Axiom to help bring their drug delivery technology to the clinic.
The technology leverages the safe delivery of nanoparticles to treat autoimmune diseases and allergies. The first application – currently supported by MTPConnect’s Targeted Translation Research Accelerator (TTRA) funding, an initiative of the Medical Research Future Fund (MRFF) – focuses on oral insulin to improve the lives of people with Type 1 Diabetes, a lifelong autoimmune disease which usually starts in young children and requires multiple daily injections of insulin. In 2021, it was estimated that 8.4 million people worldwide live with the condition.
Professor Victoria Cogger, Professor David Le Couteur AO and Dr Nicholas Hunt founded spin-off company Endo Axiom after 20 years of research.